{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:23:53Z","timestamp":1793820233784,"version":"4.6.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of Janus kinase inhibitors (JAKis) is growing in dermatology with approvals for atopic dermatitis, alopecia areata, plaque psoriasis and psoriatic arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate infectious adverse events (iAEs) associated with abrocitinib, baricitinib, deucravacitinib, ritlecitinib, tofacitinib and upadacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were retrieved from the US Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) database via the open-source AERSMine platform (Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA). Reports from the first quarter of 2004 to the second quarter of 2024 were screened under the MedDRA System Organ Class \u2018Infections and infestations\u2019 categorization. The analysis encompassed all indications, not solely dermatological use. Disproportionality metrics, including reporting odds ratio, proportional reporting ratio and information component, were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tofacitinib had the highest number of iAE reports (n = 68 669), followed by upadacitinib (n = 17 822). When stratified by sex, most reports related to women and girls. When stratified by age, iAEs were most frequently reported in individuals aged 25\u201365 years, except baricitinib, for which iAEs were more frequently reported in individuals aged \u2265 66 years. Disproportionality analysis revealed sex- and age-related differences in iAE risk, with male sex generally associated with lower risk. Paediatric patients (0\u201314\u2005years) had an elevated iAE risk with abrocitinib and upadacitinib, while adults aged \u2265 66\u2005years showed increased risk with baricitinib and tofacitinib. Commonly reported iAEs included COVID-19, herpes zoster, nasopharyngitis, influenza, urinary tract infection, pneumonia and sinusitis. Each JAKi was associated with distinct high-signal iAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To our knowledge, this is the most comprehensive real-world analysis of iAEs linked to oral JAKis to date. While infection risks varied across agents, both common and rare but serious events were identified. Findings highlight the importance of individualized monitoring and preventive strategies, and reinforce the value of postmarketing surveillance in ensuring safe JAKi use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf427","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:59:43Z","timestamp":1758283183000},"page":"226-235","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of infection risk associated with Janus kinase inhibitors: a pharmacovigilance analysis using the Food and Drug Administration\u2019s Adverse Event Reporting System database"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6920-3779","authenticated-orcid":false,"given":"Cansu","family":"Alt\u0131n\u00f6z G\u00fcney","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Dinar State Hospital , Afyonkarahisar ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-3501","authenticated-orcid":false,"given":"Huriye Ayb\u00fcke","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Giresun University Faculty of Medicine , Giresun ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"2026012711321639900_llaf427-B1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026012711321639900_llaf427-B2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/pde.15721","article-title":"Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors","volume":"41","author":"Talasila","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2026012711321639900_llaf427-B3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev Med Interne"},{"key":"2026012711321639900_llaf427-B4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jvc2.551","article-title":"Presenting JAK inhibitor safety information to dermatology patients","volume":"4","author":"Teixeira","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"2026012711321639900_llaf427-B5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","article-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials","volume":"404","author":"Bissonnette","year":"2024","journal-title":"Lancet"},{"key":"2026012711321639900_llaf427-B6","doi-asserted-by":"crossref","first-page":"2474507","DOI":"10.1080\/09546634.2025.2474507","article-title":"Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials","volume":"2025","author":"Su","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"2026012711321639900_llaf427-B7","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"2026012711321639900_llaf427-B8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/CIRCULATIONAHA.117.029233","article-title":"Reality and truth: balancing the hope and the hype of real-world evidence","volume":"136","author":"Patel","year":"2017","journal-title":"Circulation"},{"key":"2026012711321639900_llaf427-B9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026012711321639900_llaf427-B10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026012711321639900_llaf427-B11","doi-asserted-by":"crossref","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"2026012711321639900_llaf427-B12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imr.12705","article-title":"JAK\/STAT signaling in regulation of innate lymphoid cells: the gods before the guardians","volume":"286","author":"Stabile","year":"2018","journal-title":"Immunol Rev"},{"key":"2026012711321639900_llaf427-B13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/imr.13312","article-title":"JAK\/STAT defects and immune dysregulation, and guiding therapeutic choices","volume":"322","author":"Chaimowitz","year":"2024","journal-title":"Immunol Rev"},{"key":"2026012711321639900_llaf427-B14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: part I. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026012711321639900_llaf427-B15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaad.2021.06.873","article-title":"Janus kinase inhibitors in dermatology: part II. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026012711321639900_llaf427-B16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update","volume":"84","author":"Nash","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026012711321639900_llaf427-B17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdin.2024.09.012","article-title":"Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: a systematic review and meta-analysis","volume":"18","author":"Isufi","year":"2025","journal-title":"JAAD Int"},{"key":"2026012711321639900_llaf427-B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.medcli.2024.05.007","article-title":"Adverse reactions to Janus kinase inhibitors: study of their incidence and predictive factors in patients with rheumatoid arthritis","volume":"163","author":"Martinez-Molina","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"2026012711321639900_llaf427-B19","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3390\/ijms22052449","article-title":"Thromboembolic adverse drug reactions in Janus kinase (Jak) inhibitors: does the inhibitor specificity play a role?","volume":"22","author":"Kotyla","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026012711321639900_llaf427-B20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14740338.2023.2223955","article-title":"Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System database (FAERS)","volume":"22","author":"Mytheen","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"2026012711321639900_llaf427-B21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40264-025-01535-8","article-title":"Major adverse cardiovascular events related to JAK inhibitors: a disproportionality analysis using the WHO Global Individual Case Safety database","volume":"48","author":"Di Napoli","year":"2025","journal-title":"Drug Saf"},{"key":"2026012711321639900_llaf427-B22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ueg2.12736","article-title":"Gastrointestinal perforations associated with JAK inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System","volume":"13","author":"Goldman","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"2026012711321639900_llaf427-B23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010\u20132019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf"},{"key":"2026012711321639900_llaf427-B24","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2465862","article-title":"Adverse event profile of ocular injury associated with JAK inhibitors in patients with rheumatoid arthritis: a disproportionality analysis","author":"Li","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026012711321639900_llaf427-B25","author":"Drug Approval Package: CIBINQO"},{"key":"2026012711321639900_llaf427-B26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4\u2005years of exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026012711321639900_llaf427-B27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jaip.2025.02.040","article-title":"Long-term safety of abrocitinib in moderate-to-severe atopic dermatitis: integrated analysis by age","volume":"13","author":"Cork","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026012711321639900_llaf427-B28","doi-asserted-by":"crossref","first-page":"116546","DOI":"10.1016\/j.diagmicrobio.2024.116546","article-title":"Herpes virus reactivation induced by abrocitinib: a real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"110","author":"Chen","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026012711321639900_llaf427-B29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14740338.2024.2355336","article-title":"Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database","volume":"24","author":"Sun","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026012711321639900_llaf427-B30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14740338.2024.2356020","article-title":"Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system","volume":"24","author":"Zhu","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026012711321639900_llaf427-B31","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2502037","article-title":"Janus kinase inhibitors and the risk of infections: a network meta-analysis across disease indications","author":"Li","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026012711321639900_llaf427-B32","author":"European Medicines Agency"},{"key":"2026012711321639900_llaf427-B33","author":"Drug Approval Package: Olumiant (baricitinib)"},{"key":"2026012711321639900_llaf427-B34","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2217\/imt-2023-0078","article-title":"Infectious adverse events in patients with atopic dermatitis treated with baricitinib","volume":"15","author":"Antonelli","year":"2023","journal-title":"Immunotherapy"},{"key":"2026012711321639900_llaf427-B35","doi-asserted-by":"crossref","first-page":"103215","DOI":"10.1016\/j.autrev.2022.103215","article-title":"Infectious side effects of baricitinib: a big data analysis based on VigiBase","volume":"22","author":"Mahroum","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2026012711321639900_llaf427-B36","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s10067-024-06980-x","article-title":"Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs","volume":"43","author":"Opdam","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026012711321639900_llaf427-B37","author":"Drug Approval Package: SOTYKTU"},{"key":"2026012711321639900_llaf427-B38","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026012711321639900_llaf427-B39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3\u2005years: an open-label extension of randomized clinical trials","volume":"161","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026012711321639900_llaf427-B40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/bjd\/ljae406","article-title":"Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial","volume":"192","author":"Zhang","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026012711321639900_llaf427-B41","author":"Drug Approval Package: LITFULO"},{"key":"2026012711321639900_llaf427-B42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026012711321639900_llaf427-B43","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"2026012711321639900_llaf427-B44","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2527386","article-title":"Safety issues of tofacitinib in rheumatoid arthritis patients: real-world pharmacovigilance","author":"Zeng","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026012711321639900_llaf427-B45","author":"FDA Approved Drug Products"},{"key":"2026012711321639900_llaf427-B46","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026012711321639900_llaf427-B47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ibd\/izac063","article-title":"Long-term risk of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"29","author":"Winthrop","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026012711321639900_llaf427-B48","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41598-017-07261-1","article-title":"A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"2026012711321639900_llaf427-B49","author":"FDA Approved Drug Products"},{"key":"2026012711321639900_llaf427-B50","author":"European Medicines Agency"},{"key":"2026012711321639900_llaf427-B51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026012711321639900_llaf427-B52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026012711321639900_llaf427-B53","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026012711321639900_llaf427-B54","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12325-023-02732-6","article-title":"Safety of upadacitinib in immune-mediated inflammatory diseases: systematic literature review of indirect and direct treatment comparisons of randomized controlled trials","volume":"41","author":"Mysler","year":"2024","journal-title":"Adv Ther"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf427\/64331842\/llaf427.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/2\/226\/64331842\/llaf427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/2\/226\/64331842\/llaf427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:32:30Z","timestamp":1769531550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/2\/226\/8259637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,20]]},"published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf427","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,9,20]]}}}